Experienced in MYH9 Related Thrombocytopenia

Dr. James B. Bussel

Pediatric Hematology Oncology
525 E 68th St # P-695, 
New York, NY 
Experienced in MYH9 Related Thrombocytopenia
525 E 68th St # P-695, 
New York, NY 
OverviewInsuranceLocationsClinical Research

Overview

James Bussel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Bussel is rated as an Experienced provider by MediFind in the treatment of MYH9 Related Thrombocytopenia. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Anemia, Hemolysis, and Splenectomy.

His clinical research consists of co-authoring 234 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of MYH9 Related Thrombocytopenia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

525 E 68th St # P-695, New York, NY 10021

Additional Areas of Focus

Dr. Bussel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Enrollment Status: Terminated
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Enrollment Status: Completed
Publish Date: June 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
The Effect of Eltrombopag on Platelet Survival: the Role of the B-cell L Extra Large (BcL-xL) Pathway
The Effect of Eltrombopag on Platelet Survival: the Role of the B-cell L Extra Large (BcL-xL) Pathway
Enrollment Status: Completed
Publish Date: March 18, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Enrollment Status: Completed
Publish Date: November 07, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
End of EXTEND: Observing for Sustained Response Despite Discontinuation of Medication in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Treated With Eltrombopag
End of EXTEND: Observing for Sustained Response Despite Discontinuation of Medication in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Treated With Eltrombopag
Enrollment Status: Terminated
Publish Date: July 17, 2018
Intervention Type: Drug
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:
Enrollment Status: Terminated
Publish Date: July 16, 2018
The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin
The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin
Enrollment Status: Terminated
Publish Date: May 16, 2017
Intervention Type: Drug
Study Phase: Phase 4
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
Enrollment Status: Completed
Publish Date: February 01, 2017
View 8 Less Clinical Trials

234 Total Publications

Neonatal Fc Receptor - Biology and Therapeutics. Reply.
Neonatal Fc Receptor - Biology and Therapeutics. Reply.
Journal: The New England journal of medicine
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bussel's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile